HR Execs on the Move

Detroit Institute for Children

www.chrisgbur.com

 
Detroit Institute for Children is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Integrity Digital Solutions

Integrity Digital Solutions is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Temple, TX. To find more information about Integrity Digital Solutions, please visit www.integrityemr.com

Empiric Systems

Empiric Systems, LLC is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Idenix Pharmaceuticals

Idenix Pharmaceuticals, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Idenix Pharmaceuticals, Inc. is based in Cambridge, MA. You can find more information on Idenix Pharmaceuticals, Inc. at www.idenix.com

Ascend Wellness

Ascend Group Partners is a vertically integrated cannabis cultivator, processor, and dispensary operator focused on the Massachusetts, Illinois, and Michigan markets. We seek to foster a robust and inclusive cannabis industry through a premium, unmatched customer-focused retail experience.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.